- Details
- A more common but often less talked about negative side effect of androgen deprivation therapy is the presence of hot flushes in men. In this discussion with Carmel Pezaro, Mark Frydenberg highlights solutions to this issue ranging from simple everyday adaptations to investigating alternative complementary therapies and drugs. Biographies: Mark Frydenberg, MD, Vice President, President-elect, Urol...
|
- Details
- Oliver Sartor joins Charles Ryan to talk about the VISION trial, a trial testing the PSMA-617 agent, The novel therapeutic drug 177Lu-PSMA-617 is a prostate-specific membrane antigen (PSMA) targeting agent to deliver radionuclide therapy for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). The primary objective of this study is to compare the 2 alternative en...
|
- Details
- Robin Millman, a patient advocate, and 20+ year prostate cancer survivor shares a patient's perspective on the treatment landscape journey and hopes for the future of advanced prostate cancer treatment at the Advanced Prostate Cancer Consensus Conference (APCCC) 2019. Biographies: Robin Millman, a patient advocate, and 20+ year prostate cancer survivor Carmel Pezaro, BHB MBChB, FRACP, DMedSc, MHPE...
|
- Details
- Alicia Morgans hosts Bishoy Faltas in a discussion about a Nature Communications publish article Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling which Bishoy was a co-author on with Brian D Robinson et al. In this study an integrated analysis of whole-exome and RNA sequencing of upper tract urothelial carcinoma (UTUC) was performed...
|
- Details
- Shaan Dudani joins Monty Pal and Jaime Landman, sharing an overview of the First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic Renal-cell Carcinoma Database Consortium which was published this past August in European urology. Using the International Metastatic Renal-cell Carcinoma Database Consortium (IMDC) dataset, patient...
|
- Details
- Arpit Rao joins Alicia Morgans to discuss new data on PARP inhibitors in prostate cancer. Dr. Rao shares his thoughts about the future of PARP, where things stand with PARP inhibitors currently, highlighting the PROfound study, TRITON2, and last year's TOPARP-B in advanced castration-resistant prostate cancer and what he thinks in terms of personalized medicine for this population. Biographies: Ar...
|
- Details
- Darren Poon joins Alicia Morgans to discuss his presentation on pharmaco-ethnicities specifically as it relates to drug toxicities in Asian patients, and why it is important to think about on a wider scale at the 2019 Advanced Prostate Cancer Consensus Conference (APCCC). Dr. Poon addresses the importance that ethnic backgrounds have on the treatment of prostate cancer, largely arguing that these...
|
- Details
- Maha Hussain joins Alicia Morgans sharing an overview of the PROfound study design, it's intent, and specifications on how it was designed to arrive at the answer it was seeking. The PROfound Study, a Phase III, Open-Label, Randomized Study to Assess the Efficacy and Safety of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cance...
|
- Details
- Nick James and Alicia Morgans talk about the newly presented STAMPEDE data just released and presented at the 2019 ESMO meeting including, long-term follow-up of the docetaxel patients as well as the much anticipated metastatic data. Biographies: Professor Nicholas James BSc, MB, BS, FRCP, FRCR, Ph.D., Institute of Cancer and Genomic Sciences NIHR Senior Investigator, Consultant in Clinical Oncolo...
|
- Details
- Kosj Yamoah and Ngozi Ekeke join Charles Ryan to discuss the problem of prostate cancer in Africa. There is an increase in incidence and mortality as well as a late diagnosis of prostate cancer in Africa. The three discuss some of the obstacles that patients face such as lack of health education, pharmaco-ethnicity problems, high out-of-pocket costs, and geographic challenges. Biographies: Kosj Ya...
|
